GO:0042284 sphingolipid delta-4 desaturase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042284 describes the enzymatic activity that introduces a trans double bond at the C4 position of the sphingoid base, converting dihydroceramide to ceramide.
• The reaction is catalyzed by delta-4 desaturases such as DEGS1 in humans and DES1 in yeast, which are cytochrome b5-dependent and use molecular oxygen.
• This activity is the rate-limiting step in de novo ceramide synthesis and acts as a gatekeeper of ceramide-induced lipotoxicity.
• Dysregulation of delta-4 desaturase activity is linked to cancer stemness, metabolic disorders, and developmental defects.
• Rare variants in DEGS1 alter the de novo ceramide synthesis pathway and are associated with altered sphingolipid profiles.
• Studying this activity requires integrated approaches including CRISPR knockout, point mutation, and lipidomics.
Description
Sphingolipid delta-4 desaturase activity (GO:0042284) is a molecular function that catalyzes the introduction of a trans double bond at the C4 position of the sphingoid base, converting N-acylsphinganine (dihydroceramide) to N-acylsphing-4-enine (ceramide). This reaction is a critical step in the de novo sphingolipid biosynthesis pathway and determines the balance between dihydroceramides and ceramides, which have distinct biological roles. The enzyme responsible, dihydroceramide desaturase 1 (DEGS1 in humans, DES1 in yeast), is a cytochrome b5-dependent desaturase that requires molecular oxygen and reducing equivalents. The activity of delta-4 desaturase is essential for the production of ceramides, which are not only structural components of cell membranes but also potent signaling molecules involved in cell growth, differentiation, and apoptosis. Alterations in this activity have been implicated in a range of pathological conditions, including cancer, where it can enhance stem-like traits and promote tumor progression, and metabolic disorders linked to rare DEGS1 variants. Understanding the regulation and function of this enzyme is therefore of significant interest for both basic research and therapeutic development. Recent studies have highlighted the role of delta-4 desaturase in developmental processes and in the response to cytokines, further underscoring its importance in physiology. This article provides a comprehensive overview of the GO term GO:0042284, covering its definition, mechanism, key genes, disease associations, and research methodologies, with a focus on how CRISPR-based models can be used to study this activity.
sphingolipid delta-4 desaturase activity At A Glance
| GO ID | GO:0042284 |
|---|---|
| GO term | sphingolipid delta-4 desaturase activity |
| Ontology | molecular_function |
| Synonym | delta-4 sphingolipid desaturase activity |
| Major function | Catalyzes the conversion of dihydroceramide to ceramide by introducing a trans double bond at C4 |
| Reaction | an N-acylsphinganine + 2 Fe(II)-[cytochrome b5] + O2 + 2 H+ = an N-acylsphing-4-enine + 2 Fe(III)-[cytochrome b5] + 2 H2O |
| Cofactors | Cytochrome b5, molecular oxygen, Fe(II) |
| Localization | Endoplasmic reticulum membrane |
| Pathway | Sphingolipid biosynthesis (de novo ceramide synthesis) |
What Is GO:0042284?
Sphingolipid delta-4 desaturase activity (GO:0042284) is defined as the catalysis of the reaction: an N-acylsphinganine + 2 Fe(II)-[cytochrome b5] + O2 + 2 H+ = an N-acylsphing-4-enine + 2 Fe(III)-[cytochrome b5] + 2 H2O. In simpler terms, it is the enzymatic activity that removes two hydrogen atoms from dihydroceramide to form ceramide, introducing a double bond at the C4 position of the sphingoid base. This reaction is dependent on cytochrome b5 as an electron donor and molecular oxygen as an electron acceptor.
Why Is sphingolipid delta-4 desaturase activity Important in Cell Biology?
Sphingolipid delta-4 desaturase activity is a pivotal enzymatic step in sphingolipid metabolism, as it determines the ratio of dihydroceramides to ceramides, which have distinct and often opposing biological functions. Ceramides produced by this activity are essential for membrane integrity and act as second messengers in signaling pathways that regulate cell fate. Dysregulation of this activity has been linked to cancer progression, where it can promote stem-like traits and chemoresistance, as well as to metabolic and developmental disorders. Therefore, understanding its mechanism and regulation is crucial for developing therapeutic strategies targeting sphingolipid metabolism.
• Controls the balance between dihydroceramides and ceramides, which have distinct roles in cell survival and apoptosis.
• Modulates cancer stem-like traits and tumor progression through phytoceramide-mediated PI3K-AKT signaling.
• Rare variants in DEGS1 alter de novo ceramide synthesis and are associated with altered sphingolipid profiles.
• Plays a role in cytokine-dependent developmental processes and ceramide homeostasis.
• Influences skin barrier function and lipid composition in epidermal equivalents challenged with Th2 cytokines.
• Is a target for anti-cancer drugs such as ABTL0812, which increases dihydroceramide levels to induce ER stress-mediated autophagy.
• Essential for microbial production of sphingosine-1-phosphate in engineered yeast strains.
• Serves as a gatekeeper of ceramide-induced lipotoxicity, with implications for metabolic diseases.
Molecular Mechanism of sphingolipid delta-4 desaturase activity
Substrate Binding and Recognition
In simple terms: The enzyme grabs dihydroceramide and prepares it for modification.
The delta-4 desaturase enzyme binds its substrate, N-acylsphinganine (dihydroceramide), within its active site. The enzyme is a membrane-bound protein localized to the endoplasmic reticulum, where it interacts with the lipid bilayer to access its substrate. The binding is stereospecific, as the enzyme from Candida albicans has been shown to act on the D-erythro isomer of dihydroceramide.
Catalytic Desaturation
In simple terms: The enzyme removes two hydrogen atoms to create a double bond.
The desaturation reaction involves the removal of two hydrogen atoms from the C4 and C5 positions of the sphingoid base, resulting in the formation of a trans double bond at C4. This reaction requires molecular oxygen and electrons donated by cytochrome b5. The enzyme contains a di-iron center that activates oxygen for the desaturation process.
Electron Transfer via Cytochrome b5
In simple terms: Cytochrome b5 provides the electrons needed for the reaction.
The catalytic cycle depends on cytochrome b5 as an electron donor. Two molecules of Fe(II)-[cytochrome b5] are oxidized to Fe(III)-[cytochrome b5] for each molecule of dihydroceramide converted to ceramide. This electron transfer is essential for the reduction of molecular oxygen and the subsequent desaturation.
Product Release and Cellular Effects
In simple terms: The newly made ceramide is released and can act as a signaling molecule.
After the reaction, N-acylsphing-4-enine (ceramide) is released from the active site. Ceramide can then participate in various cellular processes, including membrane structure, apoptosis, and signaling. The balance between dihydroceramide and ceramide is critical, as dihydroceramides are less cytotoxic and can be converted to ceramides by this enzyme. In cancer cells, the product ceramide can enhance stem-like traits through phytoceramide-mediated PI3K-AKT signaling.
Key Genes Involved in GO:0042284 sphingolipid delta-4 desaturase activity
The following genes and proteins are directly involved in or regulate sphingolipid delta-4 desaturase activity (GO:0042284).
| Gene | Major Role | Research Relevance |
|---|---|---|
| DEGS1 | Human delta-4 desaturase; converts dihydroceramide to ceramide | Mutations linked to altered sphingolipid profiles and disease |
| DES1 (yeast) | Yeast ortholog of DEGS1; catalyzes same reaction | Model for studying enzyme mechanism and function |
| DEGS2 | Delta-4 desaturase-like protein; may have hydroxylase activity | Potential alternative enzyme in sphingolipid metabolism |
| CYB5A | Cytochrome b5; electron donor for desaturation | Essential cofactor for DEGS1 activity |
| CYB5B | Cytochrome b5 reductase; regenerates cytochrome b5 | Supports electron transfer chain |
| SPTLC1 | Serine palmitoyltransferase subunit; first step in sphingolipid synthesis | Upstream of delta-4 desaturase |
| SPTLC2 | Serine palmitoyltransferase subunit | Upstream of delta-4 desaturase |
| KDSR | 3-ketodihydrosphingosine reductase; produces dihydroceramide | Provides substrate for delta-4 desaturase |
| CERS1-6 | Ceramide synthases; produce dihydroceramide | Generate substrate for delta-4 desaturase |
| ASAH1 | Acid ceramidase; degrades ceramide | Regulates ceramide levels downstream |
| SMPD1 | Sphingomyelin phosphodiesterase; produces ceramide from sphingomyelin | Alternative ceramide source |
| SGMS1 | Sphingomyelin synthase; converts ceramide to sphingomyelin | Consumes ceramide product |
| UGCG | Glucosylceramide synthase; converts ceramide to glucosylceramide | Consumes ceramide product |
| ABCA1 | Lipid transporter; affects sphingolipid homeostasis | Indirect regulator |
| JAK/STAT | Signaling pathway regulating lipid metabolism | Modulates sphingolipid composition |
| PI3K/AKT | Signaling pathway activated by phytoceramide | Mediates cancer stem-like traits |
How Is sphingolipid delta-4 desaturase activity Regulated?
The activity of sphingolipid delta-4 desaturase is regulated at multiple levels. Transcriptional regulation of DEGS1 has been linked to cytokine signaling, particularly the JAK/STAT pathway, which influences lipid composition in epidermal equivalents. Additionally, a transcriptional network governing ceramide homeostasis establishes a cytokine-dependent developmental process, indicating that delta-4 desaturase expression is integrated into broader developmental programs. At the post-translational level, the enzyme requires cytochrome b5 and molecular oxygen, so its activity is sensitive to cellular redox status and oxygen availability. Furthermore, rare variants in DEGS1 can alter enzyme function and de novo ceramide synthesis, suggesting genetic regulation. The anti-cancer drug ABTL0812 increases dihydroceramide levels by modulating this pathway, indicating pharmacological regulation is possible.
sphingolipid delta-4 desaturase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DEGS1 | Prostate cancer stem-like traits | CRISPR knockout in prostate cancer cell lines |
| DEGS1 | Altered de novo ceramide synthesis | Point mutation knock-in in HEK293 cells |
| DEGS1 | Metabolic disorders | Liver-specific knockout mouse |
| DEGS1 | Skin barrier dysfunction | 3D epidermal equivalents with Th2 cytokines |
| DEGS1 | Cancer autophagy | Overexpression in cancer cells treated with ABTL0812 |
Cancer and Stemness
Delta-4 desaturase activity is implicated in cancer progression. In prostate cancer, the enzyme (encoded by DEGS1) enhances stem-like traits through phytoceramide-mediated PI3K-AKT signaling, suggesting that inhibitors of this activity could target cancer stem cells. Furthermore, the anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels, which are substrates for delta-4 desaturase, highlighting the therapeutic potential of modulating this pathway.
Metabolic and Developmental Disorders
Rare variants in DEGS1 significantly alter de novo ceramide synthesis, leading to changes in sphingolipid profiles that may contribute to metabolic disorders. Additionally, a transcriptional network governing ceramide homeostasis, which includes delta-4 desaturase, establishes a cytokine-dependent developmental process, linking this activity to normal development and potentially to developmental disorders.
Skin Barrier and Inflammation
In skin, JAK/STAT inhibition normalizes lipid composition in 3D human epidermal equivalents challenged with Th2 cytokines, indicating that delta-4 desaturase activity and sphingolipid metabolism are involved in inflammatory skin conditions such as atopic dermatitis.
From sphingolipid delta-4 desaturase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of DEGS1 loss on ceramide levels? | CRISPR knockout in HeLa or HEK293 cells |
| How does a rare DEGS1 variant affect enzyme activity? | Point mutation knock-in using CRISPR |
| Can DEGS1 overexpression enhance cancer stemness? | Overexpression in prostate cancer cells |
| What is the role of DEGS1 in development? | Conditional knockout mouse |
| How does DEGS1 activity affect skin lipid composition? | 3D epidermal equivalents with CRISPR knockout |
| Can DEGS1 be targeted for cancer therapy? | Xenograft models with DEGS1 knockout |
How to Study the sphingolipid delta-4 desaturase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS/MS lipidomics | Ceramide and dihydroceramide levels | Quantify enzyme activity in cells |
| In vitro desaturase assay | Conversion of dihydroceramide to ceramide | Measure kinetic parameters |
| CRISPR knockout | Loss-of-function phenotype | Study gene function in cancer cells |
| CRISPR point mutation | Effect of specific variants | Model rare DEGS1 variants |
| RNA-seq | Transcriptional changes | Identify regulatory networks |
| Proteomics | Protein expression and interactions | Study enzyme complexes |
| Immunofluorescence | Subcellular localization | Confirm ER localization |
| Flow cytometry | Cell surface markers and viability | Assess stem-like traits |
Lipidomics and Mass Spectrometry
Lipidomics using mass spectrometry is the primary method to measure the products of delta-4 desaturase activity, namely ceramides and dihydroceramides. This approach can quantify the ratio of dihydroceramide to ceramide, providing a direct readout of enzyme activity in cells or tissues.
Enzymatic Activity Assays
In vitro enzymatic assays using radiolabeled or fluorescent substrates can directly measure delta-4 desaturase activity. These assays typically use microsomes from cells expressing DEGS1 and require cytochrome b5 and NADH or NADPH as electron donors.
CRISPR-Cas9 Genome Editing
CRISPR-Cas9 knockout of DEGS1 allows researchers to study the loss-of-function phenotype, including changes in sphingolipid profiles and cellular responses. Point mutations can be introduced to model rare variants, and knock-in of tagged versions enables localization and interaction studies.
Transcriptomics and Proteomics
RNA-seq and proteomics can reveal changes in gene expression and protein levels associated with delta-4 desaturase activity, including feedback regulation and pathway crosstalk. These methods are useful for identifying transcriptional networks governing ceramide homeostasis.
How CRISPR Can Be Used to Study GO:0042284 sphingolipid delta-4 desaturase activity
Knockout
CRISPR knockout of DEGS1 is used to completely abolish delta-4 desaturase activity, leading to accumulation of dihydroceramides and depletion of ceramides. This model is valuable for studying the role of the enzyme in cancer stemness, apoptosis, and lipid metabolism.
Point Mutation
Point mutations identified in human DEGS1 variants can be introduced using CRISPR base editing or homology-directed repair to study their impact on enzyme activity and sphingolipid profiles. This approach helps establish causality between specific variants and altered ceramide synthesis.
Knock-in
Knock-in of tagged DEGS1 (e.g., FLAG or GFP) allows for visualization and immunoprecipitation of the enzyme, facilitating studies on its localization, interactions, and post-translational modifications.
Overexpression
Overexpression of DEGS1 via CRISPR activation or lentiviral delivery can increase ceramide production and has been used to study the effects on cancer cell stemness and signaling pathways such as PI3K-AKT.
How EDITGENE Supports sphingolipid delta-4 desaturase activity Research
Researchers studying sphingolipid delta-4 desaturase activity-related genes often need to determine whether a candidate gene is causally involved in ceramide metabolism, disease progression, or drug response. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional validation.
Contact EDITGENE today to design your custom CRISPR model for sphingolipid delta-4 desaturase activity research.
Frequently Asked Questions About sphingolipid delta-4 desaturase activity
What is sphingolipid delta-4 desaturase activity?
It is the enzymatic activity (GO:0042284) that converts dihydroceramide to ceramide by introducing a double bond at the C4 position of the sphingoid base, using cytochrome b5 and oxygen.
What genes are involved in sphingolipid delta-4 desaturase activity?
The primary gene is DEGS1 in humans (DES1 in yeast), which encodes the enzyme. Other genes include CYB5A and CYB5B for electron transfer, and upstream genes like SPTLC1 and KDSR.
What is the function of DEGS1?
DEGS1 encodes delta-4 desaturase, which catalyzes the final step in de novo ceramide synthesis, converting dihydroceramide to ceramide. It is a gatekeeper of ceramide-induced lipotoxicity.
How is sphingolipid delta-4 desaturase activity regulated?
It is regulated transcriptionally by cytokine signaling (e.g., JAK/STAT) and developmentally, and post-translationally by cytochrome b5 availability and redox status.
What diseases are associated with delta-4 desaturase?
It is linked to cancer (prostate cancer stemness), metabolic disorders, and skin barrier dysfunction. Rare DEGS1 variants alter ceramide synthesis.
How can I measure delta-4 desaturase activity?
Lipidomics by LC-MS/MS to measure ceramide/dihydroceramide ratios, or in vitro enzymatic assays using microsomes and cytochrome b5.
What is the role of delta-4 desaturase in cancer?
It enhances cancer stem-like traits through phytoceramide-mediated PI3K-AKT signaling, making it a potential therapeutic target.
Can CRISPR be used to study delta-4 desaturase?
Yes, CRISPR knockout, point mutation knock-in, and overexpression models are powerful tools to study DEGS1 function and its role in disease.
What are the substrates and products of delta-4 desaturase?
The substrate is N-acylsphinganine (dihydroceramide) and the product is N-acylsphing-4-enine (ceramide).
What is the clinical relevance of DEGS1 variants?
Rare DEGS1 variants significantly alter de novo ceramide synthesis and are associated with altered sphingolipid profiles, potentially contributing to metabolic and neurological disorders.
Conclusion
Sphingolipid delta-4 desaturase activity (GO:0042284) is a fundamental enzymatic function in sphingolipid metabolism, controlling the conversion of dihydroceramide to ceramide. Its dysregulation is implicated in cancer, metabolic disorders, and skin inflammation, making it a compelling target for research and therapeutic intervention. Advances in CRISPR-based models and lipidomics are enabling deeper insights into its regulation and pathophysiological roles.
References
- 1. Luo Y et al.. 2025. Delta 4-desaturase sphingolipid 2 enhances prostate cancer stem-like traits through phytoceramide-mediated PI3K-AKT signaling pathway.. Carcinogenesis 46(2) PMID: 40380873
- 2. Beckmann C et al.. 2003. Stereochemistry of a bifunctional dihydroceramide delta 4-desaturase/hydroxylase from Candida albicans; a key enzyme of sphingolipid metabolism.. Org Biomol Chem 1(14):2448-54 PMID: 12956060
- 3. Rodriguez-Cuenca S et al.. 2015. Dihydroceramide desaturase 1, the gatekeeper of ceramide induced lipotoxicity.. Biochim Biophys Acta 1851(1):40-50 PMID: 25283058
- 4. Liao R et al.. 2023. A transcriptional network governing ceramide homeostasis establishes a cytokine-dependent developmental process.. Nat Commun 14(1):7262 PMID: 37945603
- 5. Flori E et al.. 2024. JAK/STAT Inhibition Normalizes Lipid Composition in 3D Human Epidermal Equivalents Challenged with Th2 Cytokines.. Cells 13(9) PMID: 38727296
- 6. Jang IS et al.. 2024. Engineering of Saccharomyces cerevisiae as a platform strain for microbial production of sphingosine-1-phosphate.. Microb Cell Fact 23(1):310 PMID: 39550572
- 7. Blackburn NB et al.. 2019. Rare DEGS1 variant significantly alters de novo ceramide synthesis pathway.. J Lipid Res 60(9):1630-1639 PMID: 31227640
- 8. Muñoz-Guardiola P et al.. 2021. The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells.. Autophagy 17(6):1349-1366 PMID: 32397857
